A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity
Alzheimer's diseaseFrontotemporal dementiaDementia with Lewy bodiesProgressive supranuclear palsyParkinson's diseaseAmyotrophic lateral sclerosisMultiple sclerosisNeurodegenerative diseaseLongevityPLCG2Phospholipase C Gamma 2
